- freely available
Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease
AbstractThe compounds 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl nitrate (C1), (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl nitrate (C2), 3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzyl nitrate (C3), 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-hydroxy-benzenesulfonamide (C4), 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzyl nitrate (C5), and 2-[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]ethyl nitrate (C6) were evaluated with a micronucleus test using mouse peripheral blood to identify new candidate drugs for the treatment of sickle cell disease (SCD) that are safer than hydroxyurea. The compounds induced an average frequency of micronucleated reticulocytes (MNRET) of less than six per 1,000 cells at 12.5, 25, 50, and 100 mg/kg, whereas hydroxyurea induced an average MNRET frequency of 7.8, 9.8, 15, and 33.7 per 1000 cells respectively, at the same concentrations. Compounds C1–C6 are new non-genotoxic in vivo candidate drugs for the treatment of SCD symptoms.
Share & Cite This Article
Dos Santos, J.L.; Longhin Bosquesi, P.; Varanda, E.A.; Moreira Lima, L.; Chung, M.C. Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease. Molecules 2011, 16, 2982-2989.View more citation formats
Dos Santos JL, Longhin Bosquesi P, Varanda EA, Moreira Lima L, Chung MC. Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease. Molecules. 2011; 16(4):2982-2989.Chicago/Turabian Style
Dos Santos, Jean Leandro; Longhin Bosquesi, Priscila; Varanda, Eliana Aparecida; Moreira Lima, Lídia; Chung, Man Chin. 2011. "Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease." Molecules 16, no. 4: 2982-2989.
Notes: Multiple requests from the same IP address are counted as one view.